Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2024 Jul 29

PMID 39072313

Authors

Hidenori Maruyama

Fumiya Sano

Reiko Sakaguchi

Keisuke Okamoto

Itaru Miura

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the effect of lurasidone on a new, patient Life Engagement scale in schizophrenia.

Patients And Methods: This post-hoc analysis included participants (ages 18 to 74) diagnosed with schizophrenia who were randomized to lurasidone (40 mg/day) or placebo in a 6-week double-blind efficacy study and those who continued in a subsequent 12-week open-label extension study during which patients received either 40 or 80/mg day lurasidone (flexibly dosed). Change in life engagement was measured using the Positive and Negative Syndrome Scale (PANSS) 11-item Life Engagement subscale score, and individual subscale items, at week 6 during the double-blind phase and extension phase week 12 during the open-label extension phase.

Results: Analysis focused on 478 subjects randomized to lurasidone or placebo during the 6-week trial, and 146 who received lurasidone during the extension phase. During the 6-week trial, there was a significantly greater change on the PANSS Life Engagement subscale score from baseline to week 6 in the lurasidone group compared to the placebo group (mean changes of -6.4 and -4.8, respectively, p = 0.006; effect size = 0.27). Further improvement was evident during the extension phase for patients who received lurasidone in both phases, with a mean change from double-blind baseline to week 12 of the open-label treatment phase of -10.1 on in PANSS Life Engagement subscale.

Conclusion: This post-hoc analysis suggests that lurasidone may improve life engagement in patients with schizophrenia, a meaningful outcome from patients' perspective. Further studies are needed to confirm this effect.

Eudract Number: Trial registration: EudraCT Numbers: 2016-000060-42; 2016-000061-23.

References

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

Harvey P, Siu C, Ogasa M, Loebel A . Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophr Res. 2015; 166(1-3):334-8. DOI: 10.1016/j.schres.2015.06.008. View

Harvey P, Siu C, Hsu J, Cucchiaro J, Maruff P, Loebel A . Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013; 23(11):1373-82. DOI: 10.1016/j.euroneuro.2013.08.003. View

. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789-1858. PMC: 6227754. DOI: 10.1016/S0140-6736(18)32279-7. View

Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane J . Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147(1):95-102. DOI: 10.1016/j.schres.2013.03.013. View

Horisawa T, Ishiyama T, Ono M, Ishibashi T, Taiji M . Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-269970 autoradiography. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40:132-7. DOI: 10.1016/j.pnpbp.2012.08.005. View

Chong H, Teoh S, Wu D, Kotirum S, Chiou C, Chaiyakunapruk N . Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016; 12:357-73. PMC: 4762470. DOI: 10.2147/NDT.S96649. View

Bartres-Faz D, Cattaneo G, Solana J, Tormos J, Pascual-Leone A . Meaning in life: resilience beyond reserve. Alzheimers Res Ther. 2018; 10(1):47. PMC: 5968537. DOI: 10.1186/s13195-018-0381-z. View

Harvey P, Ogasa M, Cucchiaro J, Loebel A, Keefe R . Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011; 127(1-3):188-94. DOI: 10.1016/j.schres.2011.01.004. View

10.

Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R . Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1):171-81. DOI: 10.1124/jpet.110.167346. View

11.

Marder S, Meehan S, Weiss C, Chen D, Hobart M, Hefting N . Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021; 2(1):sgab014. PMC: 8650077. DOI: 10.1093/schizbullopen/sgab014. View

12.

Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y . Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study. Neuropsychiatr Dis Treat. 2021; 17:2683-2695. PMC: 8379682. DOI: 10.2147/NDT.S320021. View

13.

Saha S, Chant D, McGrath J . A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007; 64(10):1123-31. DOI: 10.1001/archpsyc.64.10.1123. View

14.

Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266-77. PMC: 3893686. DOI: 10.1176/appi.ajp.2011.10111704. View

15.

Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y . Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2021; . PMC: 8361730. DOI: 10.1111/pcn.13221. View

16.

Jacobson N, Truax P . Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991; 59(1):12-9. DOI: 10.1037//0022-006x.59.1.12. View

17.

Correll C, Ismail Z, McIntyre R, Rafeyan R, Thase M . Patient Functioning, Life Engagement, and Treatment Goals in Schizophrenia. J Clin Psychiatry. 2022; 83(5). DOI: 10.4088/JCP.LU21112AH2. View

18.

Correll C, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P . Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017; 16(2):163-180. PMC: 5428179. DOI: 10.1002/wps.20420. View

19.

Correll C, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A . Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016; 21(5):393-402. DOI: 10.1017/S1092852915000917. View

20.

Zheng W, Cai D, Yang X, Li L, Zhang Q, Ng C . Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. J Psychiatr Res. 2018; 103:244-251. DOI: 10.1016/j.jpsychires.2018.06.005. View